February 26, 2020 / 12:19 PM / in a month

BRIEF-3Sbio Inc Says NMPA Approved Clinical Trial Application For Anti-Il-5 Humanized Monoclonal Antibody Injection

Feb 26 (Reuters) - 3SBio Inc:

* NMPA APPROVES CLINICAL TRIAL APPLICATION FOR ANTI-INTERLEUKIN-5 (IL-5) HUMANIZED MONOCLONAL ANTIBODY INJECTION (“610”) Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below